# REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Study · id `cardio:ct-nct01252953` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01252953](<https://clinicaltrials.gov/study/NCT01252953>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01252953

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 30449 participants.

## Technical summary

Registry record NCT01252953. Randomized; quadruple masking; primary purpose prevention. Start 2011-06 (registry gives no type); primary completion 2017-01-31 (actual). Results posted on 2018-05-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 30449 participants (enrolled count; ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Primary completion: 2017-01-31 (actual) (ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Completion: 2037-01-31 (anticipated) (ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Results first posted: 2018-05-04 (ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Countries: United Kingdom (ClinicalTrials.gov record NCT01252953, source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01252953-2024-06-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
- Acronym: REVEAL
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Anacetrapib
- Intervention (Drug): Placebo anacetrapib
- Lead sponsor: University of Oxford
- Lead sponsor class: OTHER
- Collaborator: Merck Sharp & Dohme LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: University of Oxford (`cardio:org-university-of-oxford`)
- Registry lists this organization as a collaborator: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease (`cardio:pubmed-28847206`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease (`cardio:pubmed-34910136`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States (`cardio:pubmed-37750555`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d5b6eede96b7c5ace3409700417f10939e0cd823b06e7367c167ca7da21407f1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
